---
figid: PMC8533760__cells-10-02509-g001
figtitle: 'ERK: A Double-Edged Sword in Cancer. ERK-Dependent Apoptosis as a Potential
  Therapeutic Strategy for Cancer'
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC8533760
filename: cells-10-02509-g001.jpg
figlink: /pmc/articles/PMC8533760/figure/cells-10-02509-f001/
number: F1
caption: The regulation of RAF/MEK/ERK signaling pathway. The RAF/MEK/ERK signaling
  pathway regulates diverse cellular processes through the phosphorylation of cytoplasmic
  and nuclear proteins. Activated ERK1/2 translocates to the nucleus by Imp7 (Importin
  7) and inactive ERK1/2 is nuclear exported by Exp1 (Exportin 1). Serine/threonine
  phosphatases (PP2A and PP2Ca), tyrosine phosphatases (PTP-SL), and dual-specificity
  phosphatases (DUSP6, 7) directly dephosphorylate ERK1/2 in the cytoplasm. Dual-specificity
  phosphatases (DUSP1, 2, 5, and 9) dephosphorylate ERK1/2 in the nucleus. Abnormal
  activation of RAF/MEK/ERK1/2 signaling is known in various cancer cells. BRAF inhibitors
  (vemurafenib, dabrafenib, and encorafenib), and MEK inhibitors (trametinib, cobimetinib,
  and binimetinib) prevent ERK1/2 activation and are currently used for cancer therapy.
papertitle: 'ERK: A Double-Edged Sword in Cancer. ERK-Dependent Apoptosis as a Potential
  Therapeutic Strategy for Cancer.'
reftext: Reiko Sugiura, et al. Cells. 2021 Oct;10(10):2509.
year: '2021'
doi: 10.3390/cells10102509
journal_title: Cells
journal_nlm_ta: Cells
publisher_name: MDPI
keywords: RAS/RAF/MEK/ERK signaling | apoptosis | DUSP/MKP | cancer treatment | ACA-28
automl_pathway: 0.9515272
figid_alias: PMC8533760__F1
figtype: Figure
redirect_from: /figures/PMC8533760__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8533760__cells-10-02509-g001.html
  '@type': Dataset
  description: The regulation of RAF/MEK/ERK signaling pathway. The RAF/MEK/ERK signaling
    pathway regulates diverse cellular processes through the phosphorylation of cytoplasmic
    and nuclear proteins. Activated ERK1/2 translocates to the nucleus by Imp7 (Importin
    7) and inactive ERK1/2 is nuclear exported by Exp1 (Exportin 1). Serine/threonine
    phosphatases (PP2A and PP2Ca), tyrosine phosphatases (PTP-SL), and dual-specificity
    phosphatases (DUSP6, 7) directly dephosphorylate ERK1/2 in the cytoplasm. Dual-specificity
    phosphatases (DUSP1, 2, 5, and 9) dephosphorylate ERK1/2 in the nucleus. Abnormal
    activation of RAF/MEK/ERK1/2 signaling is known in various cancer cells. BRAF
    inhibitors (vemurafenib, dabrafenib, and encorafenib), and MEK inhibitors (trametinib,
    cobimetinib, and binimetinib) prevent ERK1/2 activation and are currently used
    for cancer therapy.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - DUSP6
  - DUSP7
  - PTPRR
  - PTPA
  - PPM1A
  - PPP2CA
  - KRAS
  - HRAS
  - NRAS
  - NPC1
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MAPK3
  - MAPK1
  - MKNK1
  - MKNK2
  - RPS6KA4
  - RPS6KA5
  - IPO7
  - ETS1
  - ETS2
  - KIF5B
  - MYLK
  - MYLK2
  - MYLK3
  - PLA2G4A
  - KAT5
  - DUSP2
  - DUSP1
  - DUSP12
  - RPS6KA1
  - RPS6KA2
  - RPS6KA3
  - RPS6KA6
  - RPS6KB1
  - RPS6KB2
  - CDC25C
  - RASGRF1
  - CDC25A
  - CDC25B
  - DUSP5
  - DUSP9
  - PALLD
  - KLC1
  - SP1
  - PSG1
  - DAND5
  - CREB1
  - CREB3
  - CREB5
  - CREB3L1
  - CREB3L2
  - CREB3L3
  - CREB3L4
  - CREM
  - ATF1
  - ATF2
  - UBTF
  - ELK1
  - KCNH4
  - KCNH8
  - XPO1
  - GDNF
  - HIF1A
  - SETD2
  - ARNT
  - FOS
  - STAT1
  - JUN
---
